Clinical UpdatesASCTCSF-1R
Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT
By MedXY|Jun 9, 2026
A new Blood study links relapse after myeloma ASCT to CSF-1R+ immunosuppressive marrow macrophages and shows that CSF-1R inhibition synergizes with lenalidomide in preclinical models, providing a strong translational rationale for post-tran